A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Mark J. Levis*, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations'. Together they form a unique fingerprint.

INIS

Biochemistry, Genetics and Molecular Biology